Human Gene Module / Chromosome 10 / EBF3

EBF3early B-cell factor 3

Score
1
High Confidence Criteria 1.1
Autism Reports / Total Reports
4 / 9
Rare Variants / Common Variants
30 / 0
Aliases
EBF3, COE3,  EBF-3,  HADDS,  O/E-2,  OE-2
Associated Syndromes
-
Genetic Category
Rare Single Gene Mutation, Syndromic
Chromosome Band
10q26.3
Associated Disorders
DD/NDD, ASD, ID
Relevance to Autism

Heterozygous mutations in the EBF3 gene are associated with hypotonia, ataxia, and delayed development syndrome (HADDS; OMIM 617330), a neurodevelopmental syndrome characterized by congenital hypotonia, delayed psychomotor development, variable intellectual disability with speech delay, variable dysmorphic facial features, and ataxia, often associated with cerebellar hypoplasia (Sleven et al., 2017; Chao et al., 2017; Harms et al., 2017; Blackburn et al., 2017); individuals in Chao et al., 2017 were reported as presenting with perseverative social behaviors and motor stereotypies. Tanaka et al., 2017 described seven novel individuals with de novo EBF3 mutations; two of these individuals presented with autism, two individuals presented with autistic features, and two individuals presented with delayed or absent social smile.

Molecular Function

This gene encodes a member of the early B-cell factor (EBF) family of DNA binding transcription factors. EBF proteins are involved in B-cell differentiation, bone development and neurogenesis, and may also function as tumor suppressors. The encoded protein inhibits cell survival through the regulation of genes involved in cell cycle arrest and apoptosis, and aberrant methylation or deletion of this gene may play a role in multiple malignancies including glioblastoma multiforme and gastric carcinoma.

External Links
Gene CardOpen Targets PlatformgnomAD browserPubMed
Human
Entrez GeneOMIMUniProtHumanBase
Fruit fly
Entrez Gene
Reports related to EBF3 (9 Reports)
# Type Title Author, Year Autism Report Associated Disorders
1 Support The contribution of de novo coding mutations to autism spectrum disorder Iossifov I et al. (2014) Yes -
2 Support De Novo Mutations in EBF3 Cause a Neurodevelopmental Syndrome. Sleven H , et al. (2016) No -
3 Support A Syndromic Neurodevelopmental Disorder Caused by De Novo Variants in EBF3. Chao HT , et al. (2016) No -
4 Support Mutations in EBF3 Disturb Transcriptional Profiles and Cause Intellectual Disability, Ataxia, and Facial Dysmorphism. Harms FL , et al. (2016) No -
5 Support Novel de novo variant in EBF3 is likely to impact DNA binding in a patient with a neurodevelopmental disorder and expanded phenotypes: patient repo... Blackburn PR , et al. (2017) No -
6 Support Whole Gene Deletion of EBF3 Supporting Haploinsufficiency of This Gene as a Mechanism of Neurodevelopmental Disease. Lopes F , et al. (2017) Yes DD, ID
7 Primary De novo variants in EBF3 are associated with hypotonia, developmental delay, intellectual disability, and autism. Tanaka AJ , et al. (2017) No Autism or autistic features
8 Support Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism Satterstrom FK et al. (2020) Yes -
9 Support Rare genetic susceptibility variants assessment in autism spectrum disorder: detection rate and practical use. Husson T , et al. (2020) Yes -
Rare Variants   (30)
Status Allele Change Residue Change Variant Type Inheritance Pattern Parental Transmission Family Type PubMed ID Author, Year
- - copy_number_loss De novo NA Simplex 29062322 Lopes F , et al. (2017)
c.907C>T p.Arg303Ter stop_gained De novo NA - 28017373 Harms FL , et al. (2016)
c.913C>T p.Gln305Ter stop_gained De novo NA - 28017373 Harms FL , et al. (2016)
c.1101+1G>T - splice_site_variant De novo NA - 28017373 Harms FL , et al. (2016)
c.486-1G>A - splice_site_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.-19G>C - missense_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.616C>T p.Arg206Ter stop_gained De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.196A>G p.Asn66Asp missense_variant De novo NA - 28017373 Harms FL , et al. (2016)
c.422A>G p.Tyr141Cys missense_variant De novo NA - 28017373 Harms FL , et al. (2016)
c.512G>A p.Gly171Asp missense_variant De novo NA - 28017373 Harms FL , et al. (2016)
c.530C>T p.Pro177Leu missense_variant De novo NA - 28017373 Harms FL , et al. (2016)
c.191A>C p.Lys64Thr missense_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.232C>T p.Gln78Ter stop_gained De novo NA Simplex 32094338 Husson T , et al. (2020)
c.355+1G>C - splice_site_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.471C>A p.His157Gln missense_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.626G>A p.Arg209Gln missense_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.-38_-37insCTTTCGGCC - inframe_insertion De novo NA - 28017373 Harms FL , et al. (2016)
c.-227_-224del - frameshift_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.487C>T p.Arg163Trp missense_variant De novo NA - 28487885 Blackburn PR , et al. (2017)
c.488G>A p.Arg163Gln missense_variant De novo NA Simplex 28017372 Chao HT , et al. (2016)
c.488G>T p.Arg163Leu missense_variant De novo NA Simplex 28017372 Chao HT , et al. (2016)
c.530C>T p.Pro177Leu missense_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.579G>T p.Lys193Asn missense_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.49G>A p.Glu17Lys splice_site_variant De novo NA Simplex 28017370 Sleven H , et al. (2016)
c.244del p.Val82TrpfsTer50 frameshift_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.1496G>C p.Gly499Ala missense_variant De novo NA Simplex 25363768 Iossifov I et al. (2014)
c.840dup p.Asp281Ter frameshift_variant De novo NA Simplex 31981491 Satterstrom FK et al. (2020)
c.625C>T p.Arg209Trp missense_variant Familial Maternal Multiplex 28017373 Harms FL , et al. (2016)
c.1402_1414del p.Thr468ProfsTer10 frameshift_variant De novo NA - 29162653 Tanaka AJ , et al. (2017)
c.616C>T p.Arg206Ter stop_gained De novo (possible germline mosaicism) - Multiplex 28017370 Sleven H , et al. (2016)
Common Variants  

No common variants reported.

SFARI Gene score
1

High Confidence

Heterozygous mutations in the EBF3 gene are associated with hypotonia, ataxia, and delayed development syndrome (HADDS; OMIM 617330), a neurodevelopmental syndrome characterized by congenital hypotonia, delayed psychomotor development, variable intellectual disability with speech delay, variable dysmorphic facial features, and ataxia, often associated with cerebellar hypoplasia (Sleven et al., 2017; Chao et al., 2017; Harms et al., 2017; Blackburn et al., 2017); individuals in Chao et al., 2017 were reported as presenting with perseverative social behaviors and motor stereotypies. Tanaka et al., 2017 described seven novel individuals with de novo EBF3 mutations; two of these individuals presented with autism, two individuals presented with autistic features, and two individuals presented with delayed or absent social smile. A de novo missense variant in the EBF3 gene was identified in an ASD proband from the Simons Simplex Collection in Iossifov et al., 2014; while this variant was novel (not present in dbSNP or ESP), it was predicted by PolyPhen-2 to be benign in Sanders et al., 2015.

Score Delta: Score remained at S

criteria met
See SFARI Gene'scoring criteria
1

High Confidence

See all Category 1 Genes

We considered a rigorous statistical comparison between cases and controls, yielding genome-wide statistical significance, with independent replication, to be the strongest possible evidence for a gene. These criteria were relaxed slightly for category 2.

1/1/2020
S
icon
S

Score remained at S

Description

Heterozygous mutations in the EBF3 gene are associated with hypotonia, ataxia, and delayed development syndrome (HADDS; OMIM 617330), a neurodevelopmental syndrome characterized by congenital hypotonia, delayed psychomotor development, variable intellectual disability with speech delay, variable dysmorphic facial features, and ataxia, often associated with cerebellar hypoplasia (Sleven et al., 2017; Chao et al., 2017; Harms et al., 2017; Blackburn et al., 2017); individuals in Chao et al., 2017 were reported as presenting with perseverative social behaviors and motor stereotypies. Tanaka et al., 2017 described seven novel individuals with de novo EBF3 mutations; two of these individuals presented with autism, two individuals presented with autistic features, and two individuals presented with delayed or absent social smile. A de novo missense variant in the EBF3 gene was identified in an ASD proband from the Simons Simplex Collection in Iossifov et al., 2014; while this variant was novel (not present in dbSNP or ESP), it was predicted by PolyPhen-2 to be benign in Sanders et al., 2015.

Reports Added
[Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism2020] [Rare genetic susceptibility variants assessment in autism spectrum disorder: detection rate and practical use.2020]
10/1/2019
S
icon
1

Increased from S to 1

New Scoring Scheme
Description

Heterozygous mutations in the EBF3 gene are associated with hypotonia, ataxia, and delayed development syndrome (HADDS; OMIM 617330), a neurodevelopmental syndrome characterized by congenital hypotonia, delayed psychomotor development, variable intellectual disability with speech delay, variable dysmorphic facial features, and ataxia, often associated with cerebellar hypoplasia (Sleven et al., 2017; Chao et al., 2017; Harms et al., 2017; Blackburn et al., 2017); individuals in Chao et al., 2017 were reported as presenting with perseverative social behaviors and motor stereotypies. Tanaka et al., 2017 described seven novel individuals with de novo EBF3 mutations; two of these individuals presented with autism, two individuals presented with autistic features, and two individuals presented with delayed or absent social smile. A de novo missense variant in the EBF3 gene was identified in an ASD proband from the Simons Simplex Collection in Iossifov et al., 2014; while this variant was novel (not present in dbSNP or ESP), it was predicted by PolyPhen-2 to be benign in Sanders et al., 2015.

Reports Added
[New Scoring Scheme]
Krishnan Probability Score

Score 0.53132184844142

Ranking 1539/25841 scored genes


[Show Scoring Methodology]
Krishnan and colleagues generated probability scores genome-wide by using a machine learning approach on a human brain-specific gene network. The method was first presented in Nat Neurosci 19, 1454-1462 (2016), and scores for more than 25,000 RefSeq genes can be accessed in column G of supplementary table 3 (see: http://www.nature.com/neuro/journal/v19/n11/extref/nn.4353-S5.xlsx). A searchable browser, with the ability to view networks of associated ASD risk genes, can be found at asd.princeton.edu.
Original Source
ExAC Score

Score 0.99859001376164

Ranking 1157/18225 scored genes


[Show Scoring Methodology]
The Exome Aggregation Consortium (ExAC) is a summary database of 60,706 exomes that has been widely used to estimate 'constraint' on mutation for individual genes. It was introduced by Lek et al. Nature 536, 285-291 (2016), and the ExAC browser can be found at exac.broadinstitute.org. The pLI score was developed as measure of intolerance to loss-of- function mutation. A pLI > 0.9 is generally viewed as highly constrained, and thus any loss-of- function mutations in autism in such a gene would be more likely to confer risk. For a full list of pLI scores see: ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3.1/functional_gene_constraint/fordist_cle aned_exac_nonTCGA_z_pli_rec_null_data.txt
Original Source
Sanders TADA Score

Score 0.94010716308957

Ranking 14448/18665 scored genes


[Show Scoring Methodology]
The TADA score ('Transmission and De novo Association') was introduced by He et al. PLoS Genet 9(8):e1003671 (2013), and is a statistic that integrates evidence from both de novo and transmitted mutations. It forms the basis for the claim of 65 individual genes being strongly associated with autism risk at a false discovery rate of 0.1 (Sanders et al. Neuron 87, 1215-1233 (2015)). The calculated TADA score for 18,665 RefSeq genes can be found in column P of Supplementary Table 6 in the Sanders et al. paper (the column headed 'tadaFdrAscSscExomeSscAgpSmallDel'), which represents a combined analysis of exome data and small de novo deletions (see www.cell.com/cms/attachment/2038545319/2052606711/mmc7.xlsx).
Original Source
Zhang D Score

Score -0.35346458549528

Ranking 17858/20870 scored genes


[Show Scoring Methodology]
The DAMAGES score (disease-associated mutation analysis using gene expression signatures), or D score, was developed to combine evidence from de novo loss-of- function mutation with evidence from cell-type- specific gene expression in the mouse brain (specifically translational profiles of 24 specific mouse CNS cell types isolated from 6 different brain regions). Genes with positive D scores are more likely to be associated with autism risk, with higher-confidence genes having higher D scores. This statistic was first presented by Zhang & Shen (Hum Mutat 38, 204- 215 (2017), and D scores for more than 20,000 RefSeq genes can be found in column M in supplementary table 2 from that paper.
Original Source
Submit New Gene

Report an Error

SFARI Gene Update

We are pleased to announce some changes to the ongoing curation of the data in SFARI Gene. In the context of a continued effort to develop the human gene module and its manually curated list of autism risk genes, we are modifying other aspects of the site to focus on the information that is of greatest interest to the research community. The version of SFARI Gene that has been developed until now will be frozen and will remain available as “SFARI Gene Archive”. Please see the announcement for more details.
Close